The Neurological Manifestations of Phelan-McDermid Syndrome - PubMed

Review

The Neurological Manifestations of Phelan-McDermid Syndrome

Yitzchak Frank. Pediatr Neurol. 2021 Sep.

Abstract

Phelan-McDermid syndrome (PMS) is a genetic disorder, caused by haploinsufficiency of the SHANK3 gene on chromosome 22q13.3. PMS is characterized by neurobehavioral symptoms and signs including intellectual disability, speech and language impairment, autism spectrum disorder (ASD), hypotonia, and other motor abnormalities. In the brain, SHANK3 is expressed in neurons, especially in the synapse, and encodes a master scaffolding protein that forms a key framework in the postsynaptic density of glutamatergic synapses. Mutations in SHANK3 have also been identified in individuals with ASD, intellectual deficiency (ID), and schizophrenia. Shank3 deficient mice have defects in basal glutamatergic synaptic transmission in the hippocampus, and in synaptic transmission plasticity, including deficits in long-term potentiation, and show behavioral deficits compatible with the clinical manifestations of PMS. The PMS phenotype varies between affected individuals, but ID and speech and language impairment are present in all cases. ASD is present in a great majority of these individuals. Neurological examination demonstrates hypotonia and abnormalities of motor coordination, visual motor coordination, and gait in the majority of affected individuals. Sleep disturbances and increased pain tolerance are frequent parental complaints. Seizures and epilepsy are common, affecting more than 40% of individuals. Brain magnetic resonance imaging abnormalities include corpus callosum hypoplasia, delayed myelination and white matter abnormalities, dilated ventricles, and arachnoid cysts. Recent advanced imaging anatomic studies including diffusion tensor imaging, point to abnormal brain connectivity. The natural history of the syndrome is not yet fully known, but some individuals with PMS have a later onset of psychiatric illnesses including bipolar disease, accompanied by functional and neurological regression. Individuals with the syndrome are treated symptomatically. Advances in understanding the pathophysiology of this syndrome and the generation of animal models have raised opportunities for a biological cure for PMS. A pilot clinical trial with insulin-like growth factor-1 (IGF-1) showed positive effects on some behavioral core symptoms.

Similar articles

• A Brazilian cohort of individuals with Phelan-McDermid syndrome: genotype-phenotype correlation and identification of an atypical case.

  Samogy-Costa CI, Varella-Branco E, Monfardini F, Ferraz H, Fock RA, Barbosa RHA, Pessoa ALS, Perez ABA, Lourenço N, Vibranovski M, Krepischi A, Rosenberg C, Passos-Bueno MR. Samogy-Costa CI, et al. J Neurodev Disord. 2019 Jul 18;11(1):13. doi: 10.1186/s11689-019-9273-1. J Neurodev Disord. 2019. PMID: 31319798 Free PMC article.

• Delineation of the genetic and clinical spectrum of Phelan-McDermid syndrome caused by SHANK3 point mutations.

  De Rubeis S, Siper PM, Durkin A, Weissman J, Muratet F, Halpern D, Trelles MDP, Frank Y, Lozano R, Wang AT, Holder JL Jr, Betancur C, Buxbaum JD, Kolevzon A. De Rubeis S, et al. Mol Autism. 2018 Apr 27;9:31. doi: 10.1186/s13229-018-0205-9. eCollection 2018. Mol Autism. 2018. PMID: 29719671 Free PMC article.

• A 29 Mainland Chinese cohort of patients with Phelan-McDermid syndrome: genotype-phenotype correlations and the role of SHANK3 haploinsufficiency in the important phenotypes.

  Xu N, Lv H, Yang T, Du X, Sun Y, Xiao B, Fan Y, Luo X, Zhan Y, Wang L, Li F, Yu Y. Xu N, et al. Orphanet J Rare Dis. 2020 Nov 30;15(1):335. doi: 10.1186/s13023-020-01592-5. Orphanet J Rare Dis. 2020. PMID: 33256793 Free PMC article.

• Phelan-McDermid Syndrome and SHANK3: Implications for Treatment.

  Costales JL, Kolevzon A. Costales JL, et al. Neurotherapeutics. 2015 Jul;12(3):620-30. doi: 10.1007/s13311-015-0352-z. Neurotherapeutics. 2015. PMID: 25894671 Free PMC article. Review.

• Phelan McDermid Syndrome: From Genetic Discoveries to Animal Models and Treatment.

  Harony-Nicolas H, De Rubeis S, Kolevzon A, Buxbaum JD. Harony-Nicolas H, et al. J Child Neurol. 2015 Dec;30(14):1861-70. doi: 10.1177/0883073815600872. Epub 2015 Sep 8. J Child Neurol. 2015. PMID: 26350728 Free PMC article. Review.

Cited by

• Targeting TrkB-PSD-95 coupling to mitigate neurological disorders.

  Yang X, Huang YA, Marshall J. Yang X, et al. Neural Regen Res. 2025 Mar 1;20(3):715-724. doi: 10.4103/NRR.NRR-D-23-02000. Epub 2024 May 13. Neural Regen Res. 2025. PMID: 38886937 Free PMC article.

• Early-onset catatonia associated with SHANK3 mutations: looking at the autism spectrum through the prism of psychomotor phenomena.

  Dhossche D, de Billy C, Laurent-Levinson C, Le Normand MT, Recasens C, Robel L, Philippe A. Dhossche D, et al. Front Psychiatry. 2023 Sep 22;14:1186555. doi: 10.3389/fpsyt.2023.1186555. eCollection 2023. Front Psychiatry. 2023. PMID: 37810596 Free PMC article.

• Drugs prescribed for Phelan-McDermid syndrome differentially impact sensory behaviors in shank3 zebrafish models.

  Kozol RA, Dallman JE. Kozol RA, et al. F1000Res. 2023 Sep 27;12:84. doi: 10.12688/f1000research.127830.2. eCollection 2023. F1000Res. 2023. PMID: 37868296 Free PMC article.

• Two Genetic Mechanisms in Two Siblings with Intellectual Disability, Autism Spectrum Disorder, and Psychosis.

  Huang YS, Fang TH, Kung B, Chen CH. Huang YS, et al. J Pers Med. 2022 Jun 20;12(6):1013. doi: 10.3390/jpm12061013. J Pers Med. 2022. PMID: 35743796 Free PMC article.

• Research Progress on Neuroprotection of Insulin-like Growth Factor-1 towards Glutamate-Induced Neurotoxicity.

  Ge L, Liu S, Rubin L, Lazarovici P, Zheng W. Ge L, et al. Cells. 2022 Feb 14;11(4):666. doi: 10.3390/cells11040666. Cells. 2022. PMID: 35203315 Free PMC article. Review.

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal